Live Breaking News & Updates on Seminal Cancer Drug

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstracts at American .
Provectus Biopharmaceuticals Inc.April 28, 2021 GMT
Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors ( NCT0269367 )
Systemic administration of PV-10 for treatment of solid tumor cancers
KNOXVILLE, TN, April 28, 2021 (GLOBE NEWSWIRE) Provectus (OTCQB: PVCT) today announced that two abstracts about data from clinical and preclinical study of investigational cancer immunotherapy PV-10 (rose bengal disodium) were accepted for the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, which will be held June 4-8 online. ....

University Of Adelaide , South Australia , United States , Heather Raines , Cumming School Of Medicine , American Society Of Clinical Oncology , National Institutes Of Health , Drug Administration , Provectus Biopharmaceuticals Inc , Head Of Clinical Oncology Research , Company Annual Report On Form , University Of Calgary , International Council On Harmonisation , American Society , Clinical Oncology , Poster Session , Gastrointestinal Cancer , Queen Elizabeth Hospital , Tim Price , Clinical Oncology Research , Medical Oncology Unit , Clinical Professor , Aru Narendran , Molecular Biology , Cumming School , Good Manufacturing Practices ,